The current study showed that cyclophosphamide exposure (expressed as PAM-Hb), varied within and between courses in breast cancer patients, regardless of treatment groups based on BSA i.e. 500 mg or 600 mg. This evidence concerns the gene GSTM1 and breast carcinoma.